Under the terms of the agreement, Complix will use its proprietary Alphabody platform to tackle two intra-cellular cancer targets. One example is the myeloid leukemia cell-1 protein (MCL-1), which regulates cell-death.
Initial in vivo data generated with their anti-MCL-1 alphabodies suggest they should have a good safety profile for a range of cancers, particularly hematological types (e.g. leukemia).
MSD will now provide an upfront payment (and potential development milestones) of up to €260M ($280M), as well as tiered royalties. In exchange, MSD will have an option to file exclusive worldwide rights to any successful Cell Penetrating Alphabodies (CPABs) which rise out of the research partnership.
CPABs enter tumor cells and tissues to selectively modulate intracellular protein-to-protein interactions (PPIs), which play a key role in the initiation and progression of cancer.